- Home
- KURA vs CMPX Comparison
KURA vs CMPX Comparison
Compare KURA & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | CMPX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 752.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KURA | CMPX |
|---|---|---|
| Price | $11.95 | $5.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $25.00 | $13.44 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,029,000.00 | N/A |
| Revenue This Year | $138.16 | N/A |
| Revenue Next Year | $67.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $1.33 |
| 52 Week High | $12.49 | $5.86 |
Technical Indicators
Market Signals| Indicator | KURA | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 67.47 |
| Support Level | $10.80 | $5.13 |
| Resistance Level | $12.32 | $5.86 |
| Average True Range (ATR) | 0.66 | 0.32 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 76.92 | 72.12 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.